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An Alu-Mediated 6-kb Duplication in the BRCA1
Gene: A New Founder Mutation?
To the Editor:
Most mutations in the breast/ovarian cancer–predispos-
ing gene BRCA1 that have been identified to date are
point mutations or small insertions and deletions scat-
tered over the whole coding sequence (5,592 nucleotides
long) and over the splice junctions (Breast Cancer In-
formation Core). Although ∼65% are unique, because
of founder effects several mutations have been found in
more than one family, both within specific populations
and in more-diverse geographic groups (Neuhausen et
al. 1996). The other germ-line mutations published so
far are five distinct large deletions (Petrij-Bosch et al.
1997; Puget et al. 1997; Swensen et al. 1997), two of
which represent 36% of all BRCA1 mutations in the
Dutch population (Petrij-Bosch et al. 1997). The im-
portance of such large genomic alterations is difficult to
estimate, because most PCR-based methods that genetic
laboratories use on genomic DNA—such as direct se-
quencing, single-strand conformation analysis (SSCA),
heteroduplex analysis (HDA), denaturing gradient gel
electrophoresis (DGGE), and the protein-truncation test
(PTT)—will not allow their detection.
Here we report the identification of the first large du-
plication in the BRCA1 gene in four apparently unre-
lated families: it comprises exon 13 and extends over 6
kb of intronic sequences. It was initially identified in one
family—F3173—originally ascertained by one of us
(H.T.L.) and contained one case of breast cancer and
four cases of ovarian cancer. Leukocytes of obligate mu-
tation carriers from F3173 had previously been shown
to present a great reduction in the amount of the mutant
transcript, but no alteration was identified in theBRCA1
coding sequence when genomic sequencing and cDNA
SSCA were performed (Serova et al. 1996). No genomic
rearrangement had been found by Southern blot anal-
ysis, and no mutation in the promoter or the 5′ and 3′
UTRs was identified by HDA (Puget et al., in press). To
look for splicing defects, we amplified, with 11 primer
pairs, cDNA synthesized from leukocyte RNA of two
patients from F3173, making sure that each exon was
entirely contained within one fragment. Because we
knew that the mutant allele was poorly expressed, we
considered any abnormal PCR fragment visualized on
agarose gels to be potentially interesting, irrespective of
its intensity. A faint extra band ∼170 bp longer than the
expected fragment was visualized in the case of patients
from F3173 with primers surrounding exons 12 and 13,
which was also seen with primers surrounding exon 13
(fig. 1a). Sequencing of this extra band revealed the pres-
ence of two consecutive exons 13, leading to a frameshift
in the mutant mRNA (ter1460). We then performed
long-range PCR on genomic DNA, with overlapping
primers in exon 13; although, as expected, no PCR prod-
uct was obtained with control DNA, an ∼6-kb fragment
was generated in F3173, indicating that an ∼6-kb du-
plication had occurred in the germ line of the F3173
patient (fig. 1b). The ∼6-kb fragment was then digested
by restriction enzymes, which showed that the dupli-
cation junction was contained within an ∼800-bp XbaI
fragment (fig. 1c). Duplication-specific primers (dup13F/
R) were designed, and a 1.1-kb fragment was PCR am-
plified and sequenced: it revealed that a 6,081-bp region
containing exon 13 (nucleotides 44369–50449 [Gen-
Bank accession number L78833]) is duplicated in F3173
(fig. 1c). Both breakpoints occurred in a 23-bp region
of perfect identity, within two Sx Alu sequences in the
same orientation (86.7% homology)—one in intron 12
and the other in intron 13—which suggests that the du-
plication is probably the result of a homologous recom-
bination.
To evaluate whether this mutation, which may have
previously escaped detection, is present in other families,
we screened, by PCR using primers dup13F/R, 52 ad-
ditional American families ascertained at Creighton Uni-
versity (of which 29 scored negative for mutations in
the coding region and splice sites of the BRCA1 gene
when analyzed by HDA and PTT). This resulted in the
identification of two more families bearing this dupli-
cation: (1) F3653, which contains seven breast cancer
cases, and (2) F2773, which contains seven breast cancer
cases and three ovarian cancer cases. The three American
families with the duplication are of mixed European
(English, Dutch, or Irish) descent. Finally, the 6-kb du-
plication was also found in one Portuguese family with
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Figure 1 Characterization of the 6-kb germ-line duplication in the BRCA1 gene in F3173. a, Complementary DNA, which was PCR
amplified with primers 12F (ACA AGC GTC TCT GAA GAC TGC) and 14R (TGC AGA CAC CTC AAA CTT GTC AGC). Only a 318-bp
fragment is generated in the control, whereas in the patient from F3173 a very faint extra band of 490 bp (unblackened arrow) containing two
consecutive exons 13 as determined by sequencing is also produced. b, Genomic DNA, which was PCR amplified with primers 13F (GAT AAA
GCT CCA GCA GGA AAT GGC) and 13R (GGC TCC CAT GCT GTT CTA AC). Only the mutant allele in F3173 gives rise to an ∼6-kb
fragment, shown (unblackened arrow), because the wild-type allele cannot be amplified with these primers (see panel c). c, Duplication of exon
13, schematically represented, with the location and orientation of primers 12F, 14R, 13F, 13R, dup13F (GAT TAT TTC CCC CCA GGC TA),
and dup13R (AGA TCA TTA GCA AGG ACC TGT G). The XbaI sites (X); introns 12 (dotted line) and 13 (broken line); and the position
and extent of the duplicated region, of the 800-bp XbaI fragment generated by the duplication, and of the 6-kb 13F/13R fragment (two-headed
arrows) are indicated.
three cases of breast cancer, when 69 families (scoring
negative for mutations in the coding region and splice
sites of BRCA1 when analyzed by DGGE [Stoppa-Lyon-
net et al. 1997]) ascertained in Paris by D.S.-L. were
screened. Although these families previously had been
subjected to quantitative Southern analysis (Puget et al.,
in press), this rearrangement was missed because, on the
one hand, the extra bands generated by digestions with
the selected restriction enzymes were identical or very
similar in size to the normal fragments, and, on the other
hand, the densitometric analysis does not allow dupli-
cations to be identified as easily as deletions (1.5-fold
signal-strength difference in duplications, compared
with a 2-fold difference in deletions).
All four families were found to bear exactly the same
duplication, as revealed by the sequencing of the dupli-
cation junction. A founder effect is very likely, since all
families could share the same haplotype at nine poly-
morphic short tandem-repeat markers within or flanking
the BRCA1locus (D17S776, D17S1185, D17S1320,
D17S855, D17S1322, D17S1323, D17S1327,
D17S1326, and D17S1329). Of the shared alleles, those
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at D17S1185 and D17S855 have a population frequency
!15%. Given the geographic diversity displayed by these
four families’ ancestors, the 6-kb duplication might be
relatively old and is therefore likely to be found in other
families around the world. Apart from the two frequent
BRCA1 mutations 185delAG and 5382insC, which have
been found four and five times, respectively, this dupli-
cation is the most frequent mutation identified in the set
of American families ascertained by H.T.L. (3 of 40
BRCA1 mutations).
Although this duplication was identified by reverse-
transcription PCR, it should be noted that it could be
easily missed, since the mutant allele is poorly expressed,
presumably because of premature stop codon–mediated
mRNA decay. Given the high concentration of Alu se-
quences in the BRCA1 gene (Smith et al. 1996), founder
rearrangements such as the one reported here could ex-
plain a substantial fraction of the estimated 37% of
breast/ovarian cancer families whose disease is due to
BRCA1 but for whom no mutation has been identified
so far in the BRCA1 coding sequence (Ford et al. 1998).
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